Press Releases

Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at the European Respiratory Society International Congress

LEXINGTON, Mass., Sept. 17, 2018 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present preclinical data on the anti-inflammatory activity of PUR1800 (RV1162) at the ERS International Congress 2018 in Paris, France.

Pulmatrix logo (PRNewsFoto/Pulmatrix, Inc.)

Aidan Curran, PhD and Senior Director, Research at Pulmatrix Inc will present preclinical data in an abstract entitled "PUR1800 (RV1162), a novel narrow spectrum kinase Inhibitor, but not fluticasone, reduces TNFα-induced cytokine release by primary bronchial epithelial cells from healthy volunteers and COPD patients" at 8:30AM on Wednesday, September 19.

"This data supports the anti-inflammatory activity of PUR1800 (RV1162) in primary cells cultured from healthy subjects and COPD patients," said David Hava, PhD, chief scientific officer of Pulmatrix.  "These preclinical studies, together with our recently completed IND-enabling non-clinical safety inhalation studies, continue to support the development of PUR1800 as a therapy to treat acute exacerbations of COPD.  We look forward to advancing PUR1800 to the clinic."

About Pulmatrix    
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases including asthma and chronic obstructive pulmonary disease ("COPD"). In addition, Pulmatrix has partnered with Vectura Group plc to develop Pulmatrix's drug candidate, PUR0200, for COPD for the U.S. market. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K filed by the Company with the Securities and Exchange Commission on March 13, 2018, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact

Robert Clarke, CEO 

William Duke, CFO       

(781) 357-2333

(781) 357-2333


SOURCE Pulmatrix, Inc.